Enhanced PKC activity contributes to the pathophysiology of several disorders, and pharmacological PKC inhibition has therefore been suggested as a therapeutic approach in multiple diseases including cancer, sequelae of diabetes, cardiovascular diseases, or inflammatory disorders such as psoriasis [55]. This evidence concerns the gene PRRT2 and cancer.